June 3, 2021 11:46 AM EDTUpdated 12:10 PM
R&D

#AS­CO21: No­var­tis flash­es 'ground­break­ing data' for $2B ra­di­oli­gand drug

Jason Mast

Editor

Here’s the “ground­break­ing” da­ta from the prostate can­cer drug No­var­tis spent $2 bil­lion to ac­quire: The mol­e­cule hit every end­point in the Phase III tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times